Location: Tech South
Program: Tech South Incubator
Industry: Life Sciences / Bio Technology
Nostopharma develops treatment to prevent pathologic bone growth – a painful complication after traumas and severe burns affecting thousands of patients world-wide. Pathologic bone growth (clinical term is Herotopic Ossification) is an unmet medical need. It is a severe pathology that results in chronic pain and loss of motion. In severe cases joint immobility and even cardio complications can arise. The treatment we are developing (NP-101) is a single injection formulated in the proprietary target delivery formulation. It is a re-purposed drug platform technology. Nostopharma is a preclinical stage, woman-owned company based in Maryland.